BDTX Stock — Black Diamond Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.96

Market cap

$112.6M

Cash

$110.5M

Enterprise value

$2.1M

Balance sheet

Cash	$110.5M
Debt	$0.0M
Net cash	$110.5M
Enterprise value	$2.1M
Basic shares	57.4M shares
Fully diluted shares	73.5M shares
Fully diluted market cap	$144.1M
Cash per share	$1.93

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BDTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2028 - Jan 24, 2029	silevertinib in combination with temozolomide	Phase 2	Glioblastoma (GBM); Newly Diagnosed Glioblastoma; GBM	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Silevertinib

Phase 2 · Active

Aliases BDTX-1535

Target EGFR

Indications

EGFR-mutant non-small cell lung cancer (NSCLC) (Phase 2)
Newly diagnosed EGFRvIII+ glioblastoma (GBM) (Phase 2)

Catalysts

— first half of 2028

Status note Brain-penetrant covalent 4th-generation EGFR MasterKey inhibitor. Phase 2 trials in frontline and 2L/3L EGFRm NSCLC (150 mg QD selected for pivotal development after ASCO May 2026 data) and a randomized Phase 2 in newly diagnosed EGFRvIII+/MGMT-unmethylated GBM (silevertinib + TMZ vs TMZ, ~150 patients; first patient dosed May 2026). Company is exploring partnership opportunities to advance silevertinib into pivotal development.

BDTX-4933

Stage not disclosed · Active Modality: small molecule

Aliases S241656

Target RAF/RAS

Partnerships Servier Pharmaceuticals: worldwide license (Mar 2025); $70.0M upfront; up to $710.0M development and commercial milestones; tiered royalties on global net sales. Servier leads development and worldwide commercialization.

Indications

RAF/RAS-mutant solid tumors (incl. NSCLC) (Stage not disclosed)

Status note Filing describes BDTX-4933 as a 'second clinical-stage asset' but does not state the clinical phase; BDTX deprioritized it internally before licensing to Servier.

BDTX-4876

Stage not disclosed · Active

Target FGFR2/FGFR3

Status note Company is evaluating strategic alternatives for BDTX-4876; the excerpts state no target, modality, indication, or clinical stage.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	silevertinib in combination with temozolomide
Lead indication	Glioblastoma (GBM)
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07326566	Phase 2	Recruiting	Sponsor	BDTX	—	Glioblastoma (GBM); Newly Diagnosed Glioblastoma; GBM	—
NCT05256290	Phase 2	Active, not recruiting	Sponsor	BDTX	—	Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Black Diamond Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

BDTX — Black Diamond Therapeutics Inc.